PDGFRA and glioma: Despite the known intratumoral heterogeneity of its somatic alterations, PDGFRA is considered a therapeutic target based on abated growth upon treatment with PDGFRA inhibitors and reduced viability after genetic knockout of PDGFRA in models of DMG-H3 K27-a glioma [14, 16].